Literatur
- 1
Adcock I M, Caramori G, Chung K F.
New targets for drug development
in asthma.
Lancet.
2008;
372
1073-1087
- 2
Alkhalil M, Schulman E, Getsy J.
Obstructive sleep apneasyndromeand asthma: what are the links?.
J Clin Sleep Med.
2009;
5
71-78
- 3
Anderson G P.
Endotyping asthma: new insights into key pathogenic mechanisms
in a complex, heterogenous disease.
Lancet.
2008;
372
1107-1119
- 4
Antoniou K M, Nicholson A G, Dimadi M. et al .
Long-term clinical effects of interferon gamma-1ß and
colchicine in idiopathic pulmonary fibrosis.
Eur Respir
J.
2006;
28
496-504
- 5
Antoniu S A.
Targeting the endothelin pathway in the idiopathic pulmonary
fibrosis: the role of bosentan.
Expert Opin Ther Targets.
2008;
12
1077-1084
- 6
Azuma A, Nukiwa T, Tsuboi E. et
al .
Double-blind, placebo-controlled trial of pirfenidone
in patients with idiopathic pulmonary fibrosis.
Am J Respir
Crit Care Med.
2005;
171
1040-1047
- 7
Bateman E D, Hurd S S, Barnes P J. et al .
Global strategy for asthma
management and prevention: GINA executive summary.
Eur
Respir J.
2008;
31
143-178
- 8
Baur X, Heger M, Köhler D. et al .
Diagnostik und Begutachtung der Berufskrankheit
Nr 4101 Quarzstaublungenerkrankung (Silikose).
Pneumologie.
2008;
62
659-684
- 9
Beeh K M, Derom E, Kanniess F, Cameron R B, Higgins M W, van As A.
Indacaterol,
a novel inhaled ß2-agonist, provides sustained 24-h bronchodilation
in asthma.
Eur Respir J.
2007;
29
871-878
- 10
Bhattacharjee R, Kheirandish-Gozal L, Pillar G, Gozal D.
Cardiovacular complications
of obstructive sleep apnea syndrome: evidence from children.
Prog
Cardiovasc Dis.
2009;
51
416-433
- 11
Bradshaw T A, Matusiewicz S P, Crompton G K, Innes J A, Greening A P.
Intravenous
magnesium sulphate provides no additive benefit to standard management
in acute asthma.
Respir Med.
2008;
102
142-149
- 12
Chanez P, Burge S, Dahl J, Creemers J, Lamarca R, Garcia
Gil E.
Once-daily administration of aclidinium
bromide, a novel, long-acting anticholinergic: a phase II, dose-finding
study (abst.).
Am J Respir Crit Care Med.
2008;
177
A349
- 13
Chiba Y, Arima J, Sakai H, Misawa M.
Lovastatin inhibits bronchial hyperresponsiveness
by reducingRhoA signaling in rat allergic asthma.
Am J
Physiol Lung Cell Mol Physiol.
2008;
294
L705-L713
- 14
Christie J D, Edwards L B, Aurora P. et al .
Registry of the International Society for Heart
and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation
report – 2008.
J Heart Lung Transplant.
2008;
27
957-969
- 15
Cohen J, Douma W R, ten H acken
NH, Vonk J M, Oudkerk M, Postma D S.
Ciclesonide
improves measures of small airway involvement in asthma.
Eur
Respir J.
2008;
31
1213-1220
- 16
Demedts M, Behr J, Buhl R. et
al .
High-dose acetylcysteine in idiopathic pulmonary
fibrosis.
N Engl J Med.
2005;
353
2229-2242
- 17
Denning D W, O’Driscoll B R, Powell G. et al .
Randomized controlled trial
of oral antifungal treatment for severe asthma with fungal sensitization.
The fungal asthma sensitization trial (FAST) study.
Am
J Respir Crit Care Med.
2008;
179
11-18
- 18
Fabbri L M, Luppi F, Beghe B, Rabe K F.
Complex chronic comorbidities
of COPD.
Eur Respir J.
2008;
31
212
- 19
Gillissen A, Wirtz H, Hoheisel G B.
Paradigmenwechsel in der Therapieempfehlung des Asthma bronchiale.
Med Klinik.
2007;
102
399-403
- 20
Gontijo-Amaral C, Ribeiro M A, Gontijo L S, Condino-Neto A, Ribeiro J D.
Oral magnesium supplementation
in asthmatic children: a double-blind randomized placebo-controlled
trial.
Eur J Clin Nutr.
2007;
61
54-60
- 21
Groome P A, Bolejack V, Crowley J J. et al .
The IASLC Lung Cancer Staging Project:
validation of the proposals for the revision of the T, N, and M
descriptors and consequent stage groupings in the forthcoming (seventh)
edeition of the TNM classification of malignant tumors.
J
Thorac Oncol.
2007;
2
603-612
- 22
Haldar P, Brightling C E, Hargadon B. et al .
Mepolizumab and exacerbations of refractory
eosinophilic asthma.
N Engl J Med.
2009;
360
973-984
- 23
Holt P G, Sly P D.
Prevention of
allergic respiratory disease in infants: current aspects and future
perspectives.
Curr Opin Allerg Clin Immunol.
2007;
7
547-555
- 24
Hothersall E J, Chaudhuri R, McSharry C. et al .
Effects of atorvastatin added to inhaled corticosteroid
on lung function and sputum cell counts in atopic asthma.
Thorax.
2008;
63
1070-1075
- 25
King jr T E, Behr J, Brown K K. et al .
BUILD-1: a randomized placebo-controlled
trial of bosentan in idiopathic pulmonary fibrosis.
Am
J Respir Crit Care Med.
2008;
177
75-81
- 26
Magnussen H, Kirsten A -M, Köhler D, Morr H, Sitter H, Worth H.
Leitlinien zur Langzeit-Sauerstofftherapie
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin
e. V.
Pneumologie.
2008;
62
748-746
- 27
Make B J, Kanniess F, Bateman E D, Linberg S E.
Efficacy of
3 different doses of carmoterol, a long-acting beta2-agonist in
patients with COPD (abst.).
Am J Respir Crit Care Med.
2008;
177
A961
- 28
Mannino D M, Thorn D, Swensen A, Holguin F.
Prevalence and outcomes
of diabetes, hypertension and cardiovascular disease in COPD.
Eur Respir J.
2008;
32
962-969
- 29
Mohammed S, Goodacre S.
Intravenous and nebulised
magnesium sulphate for acute asthma: systematic review and meta-analysis.
Emerg Med J.
2007;
24
823-830
- 30
Nair P, Pizzichini M M, Kiarsgaard M. et al .
Mepolizumab for prednisone-dependent asthma
with sputum eosinophilia.
N Engl J Med.
2009;
360
985-993
- 31
Pacanowski M A, Amsden G W.
Interferon gamma-1ß in
the treatment of idiopathic pulmonary fibrosis.
Ann Pharmacother.
2005;
39
1678-1686
- 32
Rabe K F, Bateman E D, O’Donnell D E, Witte S, Bredenbröker D, Betsuyaku T.
Roflumilast – an
oral anti-inflammatory treatment for chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
2005;
366
563-571
- 33
Raghu G, Brown K K, Costabel U. et al .
A randomized placebo controlled trial assessing the
efficacy and safety of etanercept in patients with idiopathic pulmonary
fibrosis (IPF).
Am J Respir Crit Care Med.
2008;
178
948-955
- 34
Randerath W, Lorenz J, Windisch W. et al .
Betreuung von Patienten mit maschineller Beatmung
unter häuslichen und heimpflegerischen Bedingungen.
Pneumologie.
2008;
62
305-308
- 35
Shaw D E, Berry M A, Thomas M. et al .
The use of exhaled nitric oxide to guide
asthma management.
Am J Respir Crit Care Med.
2007;
176
231-237
- 36
Singh S, Loke Y K, Furberg C D.
Inhaled anticholingergics and risk of major
adverse cardiovascular events in patients with chronic obstructive
pulmonary disease.
JAMA.
2008;
100
1439-1450
- 37
Smith A D, Cowan J O, Brasset K P, Herbison G P, Taylor D R.
Use of exhaled nitric oxide measurements
to guide treatment in chronic asthma.
N Engl J Med.
2005;
352
2163-2173
- 38
Tashkin D P, Celli B R, Senn S. et al .
A 4-year trial of tiotropium in chronic
obstructive pulmonary disease.
N Engl J Med.
2008;
359
1543-1554
- 39
Tzortzaki E G, Antoniou K M, Zervou M I. et al .
Effects of antifibrotic
agents on TGF-beta1, CTGF and IFN-gamma expression in patients with
idioapathic pulmonary fibrosis.
Respir Med.
2007;
101
1821-1829
- 40
Watz H, Waschki B, Meyer T, Magnussen H.
Physical activity in patients
with COPD.
Eur Respir J.
2009;
33
362-272
- 41
Welte T, Köhnlein T.
Global and local
epidemiology of community-acquired pneumonia: the experince of the
CAPNETZ Network.
Semin Respir Crit Care Med.
2009;
30
127-135
- 42
Wenzel S E, Wilbraham D, Fuller R, Burmeister E, Longphre M.
Effect of in interleukin-4 variant on late phase asthmatic response to
allergen challenge in asthmatic patients:results of two phase 2a
studies.
Lancet.
2007;
370
1422-1431
- 43
Wu P, Dupont W D, Griffin M R. et al .
Evidence of a causal role of winter virus
infection during infancy in early childhood asthma.
Am
J Respir Crit Care Med.
2008;
178
1123-1129
Prof. Dr. A. Gillissen
Robert-Koch-Klinik, Thoraxzentrum des Klinikums
St. Georg
Nikolai-Rumjanzew-Str. 100
04207 Leipzig
Phone: 0341/4231-202
Fax: 0341/4231-203
URL: http://www.rkk-leipzig.de